CN110381949B - 杂环化合物及其用途 - Google Patents

杂环化合物及其用途 Download PDF

Info

Publication number
CN110381949B
CN110381949B CN201880005371.5A CN201880005371A CN110381949B CN 110381949 B CN110381949 B CN 110381949B CN 201880005371 A CN201880005371 A CN 201880005371A CN 110381949 B CN110381949 B CN 110381949B
Authority
CN
China
Prior art keywords
compound
preparation
concentrated
independently
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880005371.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110381949A (zh
Inventor
石全
夏克山
吴建煌
周铭城
宋政勳
王昀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of CN110381949A publication Critical patent/CN110381949A/zh
Application granted granted Critical
Publication of CN110381949B publication Critical patent/CN110381949B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880005371.5A 2017-01-10 2018-01-08 杂环化合物及其用途 Active CN110381949B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444601P 2017-01-10 2017-01-10
US62/444601 2017-01-10
PCT/US2018/012748 WO2018132326A1 (en) 2017-01-10 2018-01-08 Heterocyclic compounds and use thereof

Publications (2)

Publication Number Publication Date
CN110381949A CN110381949A (zh) 2019-10-25
CN110381949B true CN110381949B (zh) 2023-12-08

Family

ID=62839630

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880005371.5A Active CN110381949B (zh) 2017-01-10 2018-01-08 杂环化合物及其用途

Country Status (10)

Country Link
US (1) US10882854B2 (enExample)
EP (1) EP3568137A4 (enExample)
JP (1) JP6982716B2 (enExample)
KR (1) KR102335082B1 (enExample)
CN (1) CN110381949B (enExample)
AU (1) AU2018208366B2 (enExample)
CA (1) CA3047146C (enExample)
RU (1) RU2756055C2 (enExample)
TW (1) TWI664174B (enExample)
WO (1) WO2018132326A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110176278B (zh) * 2019-05-24 2021-09-28 河海大学 氨基酸氯化生成二氯乙腈的连续反应动力学模型建模方法
WO2023014611A1 (en) * 2021-08-02 2023-02-09 Yeh, Teng-Kuang Pyrimidine compounds and use thereof
TW202345843A (zh) * 2022-04-06 2023-12-01 財團法人國家衛生研究院 脂質奈米顆粒及脂質體

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207465A (zh) * 2014-09-22 2017-09-26 财团法人卫生研究院 杂环化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW550258B (en) * 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
WO2004052862A1 (ja) * 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
KR101354114B1 (ko) 2005-06-14 2014-01-24 타이젠 바이오테크놀러지 컴퍼니 리미티드 피리미딘 화합물
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
WO2008001070A1 (en) 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
US8222256B2 (en) * 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
SI2268635T1 (sl) * 2008-04-21 2015-10-30 Taigen Biotechnology Co., Ltd. Heterociklične spojine
AU2009282567B2 (en) 2008-08-20 2014-10-02 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207465A (zh) * 2014-09-22 2017-09-26 财团法人卫生研究院 杂环化合物及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
rhEPO对预处理低氧损伤胶质细胞MMP-9表达的影响;蒋光元等;《科技导报》;20100328(第06期);全文 *
祖细胞和干细胞与缺血性疾病的治疗;张航;王照飞;张百灵;何晋;郑昭芬;;中国动脉硬化杂志(05);全文 *
骨髓干细胞动员在心脑血管疾病中的研究进展;陈海旭;杨超;徐文焕;张晓梅;曾强;;中国科学:生命科学(12);全文 *

Also Published As

Publication number Publication date
CA3047146A1 (en) 2018-07-19
EP3568137A1 (en) 2019-11-20
CA3047146C (en) 2021-08-31
RU2756055C2 (ru) 2021-09-24
RU2019124448A (ru) 2021-02-12
WO2018132326A1 (en) 2018-07-19
RU2019124448A3 (enExample) 2021-02-26
AU2018208366B2 (en) 2020-12-17
EP3568137A4 (en) 2020-05-27
NZ754272A (en) 2021-05-28
US20180208588A1 (en) 2018-07-26
KR20190104334A (ko) 2019-09-09
KR102335082B1 (ko) 2021-12-06
BR112019013493A2 (pt) 2020-01-07
JP6982716B2 (ja) 2021-12-17
TW201831466A (zh) 2018-09-01
AU2018208366A1 (en) 2019-06-27
JP2020506879A (ja) 2020-03-05
TWI664174B (zh) 2019-07-01
US10882854B2 (en) 2021-01-05
CN110381949A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
CN111225665B (zh) 大环免疫调节剂
JP6985388B2 (ja) ケモカイン受容体調節剤及びそれの使用
US7030118B2 (en) Pyrrolotriazinone compounds and their use to treat diseases
JP6615207B2 (ja) 複素環式化合物及びその使用
EP3385257A1 (en) 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
AU2015362089B2 (en) Dislodgement and release of HSC using alpha 9 integrin antagonist and CXCR4 antagonist
EP2142547A1 (en) Purinyl derivatives and their use as potassium channel modulators
CN110381949B (zh) 杂环化合物及其用途
CN108601773B (zh) 作为pi3k/mtor抑制剂的稠合喹啉化合物
GB2548542A (en) Compounds
JP2025516002A (ja) ピリミジノン含有１７－ベータ－ヒドロキシステロイドデヒドロゲナーゼ１３型阻害剤
HK40010586A (en) Heterocyclic compounds and use thereof
CN116323607A (zh) 用作alk5抑制剂的萘啶衍生物
BR112019013493B1 (pt) Compostos heterocíclicos e seus usos, composição farmacêutica e método de mobilização de células-tronco hematopoiéticas e células progenitoras endoteliais na circulação periférica
CN107405331A (zh) 使用α9整联蛋白拮抗剂从骨髓干细胞龛迁移和释放HSC
NZ754272B2 (en) Heterocyclic compounds and use thereof
KR20250087566A (ko) Bcl6의 알킬아민 함유 소분자 분해제
HK1238644B (zh) 杂环化合物及其用途
HK1227019B (en) 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
HK1187337A1 (zh) 喹唑啉二酮及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40010586

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20210615

Address after: Miaoli County, Taiwan, China

Applicant after: NATIONAL HEALTH RESEARCH INSTITUTES

Address before: indiana

Applicant before: Shi Quan

Applicant before: NATIONAL HEALTH RESEARCH INSTITUTES

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant